Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators.

[1]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[2]  R. Califf,et al.  Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. , 1994, Journal of the American College of Cardiology.

[3]  J. Mcmanus.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial: The TIMI IIIB Investigators Circulation 89:1545–1556 Apr 1994 , 1994 .

[4]  L. Tavazzi,et al.  Predictors of nonfatal reinfarction in survivors of myocardial infarction after thrombolysis. Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) Data Base. , 1994, Journal of the American College of Cardiology.

[5]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[6]  C. Cannon,et al.  A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. , 1994, Journal of the American College of Cardiology.

[7]  L. Wilkins.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. , 1994, Circulation.

[8]  E. Braunwald,et al.  Two- and three-year results of the thrombolysis in myocardial infraction (TIMI) phaes II clinical trial , 1993 .

[9]  U. Goldbourt,et al.  Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction , 1993 .

[10]  R. Temple,et al.  More on the survival and ventricular enlargement trial. , 1993, The New England journal of medicine.

[11]  J O'Keefe,et al.  A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .

[12]  R. Diaz,et al.  Significance of Smoking in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction Experience Gleaned From the International Tissue Plasminogen Activator/Streptokinase Mortality Trial , 1993, Circulation.

[13]  R M Whitlock,et al.  Prognosis after recovery from myocardial infarction: the relative importance of cardiac dilatation and coronary stenoses. , 1992, European heart journal.

[14]  E. Braunwald,et al.  An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. , 1992, Circulation.

[15]  E. Braunwald,et al.  Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II , 1992, Circulation.

[16]  David Hunt,et al.  ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION , 1992 .

[17]  H. Hellstrom.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.

[18]  A. LaCroix,et al.  Smoking and mortality among older men and women in three communities. , 1991, The New England journal of medicine.

[19]  E. Gilpin,et al.  Factors associated with recurrent myocardial infarction within one year after acute myocardial infarction. , 1991, American heart journal.

[20]  W. Rogers,et al.  Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. , 1991, Circulation.

[21]  J. Owens,et al.  Features of "near-death experience" in relation to whether or not patients were near death , 1990, The Lancet.

[22]  E J Topol,et al.  Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. , 1990, Circulation.

[23]  K. Lee,et al.  Two-year outcome after angiographically documented myocardial reperfusion for acute coronary occlusion. Thrombolysis and Angioplasty Study Group. , 1990, The American journal of cardiology.

[24]  R. Califf,et al.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.

[25]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[26]  T. A. S. Group.  In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin , 1990, The Lancet.

[27]  A. Skene,et al.  Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study , 1990, The Lancet.

[28]  J. Gore,et al.  Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. , 1990, Circulation.

[29]  K. Lee,et al.  One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. , 1990, American heart journal.

[30]  A. Moss,et al.  Prognosis and management after a first myocardial infarction. , 1990, The New England journal of medicine.

[31]  David Oakes,et al.  Prognostic significance of nonfatal myocardial reinfarction , 1990 .

[32]  K. Lee,et al.  Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. , 1989, Circulation.

[33]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[34]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[35]  Y. Ohtsuki,et al.  ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.

[36]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[37]  S. Shapiro,et al.  The risk of myocardial infarction after quitting smoking in men under 55 years of age. , 1985, The New England journal of medicine.

[38]  J L Ritchie,et al.  The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. , 1985, The New England journal of medicine.

[39]  P. Mcmaster,et al.  Nonfatal cardiac events and recurrent infarction in the year after acute myocardial infarction. , 1984, Journal of the American College of Cardiology.

[40]  C. Wild,et al.  Prognosis after recovery from first acute myocardial infarction: determinants of reinfarction and sudden death. , 1984, The American journal of cardiology.

[41]  J L Ritchie,et al.  Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. , 1983, The New England journal of medicine.

[42]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[43]  Barr Jb,et al.  HOME OR AWAY? , 1964, Lancet.

[44]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[45]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[46]  E. Braunwald,et al.  Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. , 1993, Journal of the American College of Cardiology.

[47]  Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. GISSI-2 and International Study Group. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto. , 1992, European Heart Journal.

[48]  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.

[49]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[50]  D. Cox.  Regression Models and Life-Tables , 1972 .

[51]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .